Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028
Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028
Summary
Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape, or other violent personal assault. Symptoms include “re-experiencing” distressing memories, hypervigilance, avoidant behaviors, sweating, tremors, and dissociation.
The total Post-Traumatic Stress Disorder (PTSD) market was estimated to be worth US$211.4m across the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) in 2018. This is expected to grow at a compound annual growth rate (CAGR) of 18.7% to reach US$1.2bn by 2028. Lack of efficacy is the most pressing unmet need in the Post-Traumatic Stress Disorder (PTSD) market and there have been no approved products to treat the disorder since 2001.
However, two drug candidates in the Post-Traumatic Stress Disorder (PTSD) pipeline that are expected to launch in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) by 2022 are set to revolutionize the treatment of the disorder, as evidenced by promising results in clinical trials. Zoloft and Paxil, currently the only two approved products in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) for Post-Traumatic Stress Disorder (PTSD), are antidepressants of the selective-serotonin reuptake inhibitors (SSRIs) class. The fact that Zoloft and Paxil work via the same mechanism of action means that they have the same unpleasant side effects as well as boxed warnings for impulsiveness and suicidal behaviors.
Brexpiprazole, an atypical antipsychotic approved for the treatment of major depressive disorder and schizophrenia, is in the pipeline for Post-Traumatic Stress Disorder (PTSD) and has shown efficacy when administered as an adjunct to Zoloft. The well-established safety profile and low frequency of adverse effects puts brexpiprazole in good stead to become the highest selling drug in the market, with forecasted annual sales of US$361.7m by 2028.
MDMA is a stimulant and late-stage pipeline product which was given breakthrough designation by the FDA, despite being a widely abused recreational drug. Its superior efficacy to marketed therapies and low frequency of administration are likely to be viewed favorably by physicians and patients alike. It is expected that in its first year on the market, MDMA is set to acquire a large patient share in the US as the first new drug for chronic Post-Traumatic Stress Disorder (PTSD) to be approved in 18 years. Brexpiprazole and MDMA are set to make up 47% of drug sales in 2022 and this figure will climb to 59% in 2028.
This potential for high sales whilst addressing the longstanding clinical unmet needs for the indication is clear assurance of the increasing efforts to add Post-Traumatic Stress Disorder (PTSD) to the list of psychiatric disorders that will experience market growth in the coming years and beyond.
The report “Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028” provides an overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Post-Traumatic Stress Disorder (PTSD) therapeutics market
Key Questions Answered:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook